In another cohort study including type 2 diabetes mellitus patients in Hong Kong, SGLT2 inhibitors were found to significantly reduce the risk of new-onset dementia compared to DPP-4 inhibitors. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.